RecruitingPhase 1Phase 2NCT07464132
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
Sponsor
Peking Union Medical College Hospital
Enrollment
30 participants
Start Date
Dec 17, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a new PET/CT imaging agent called [68Ga]Ga-NI-FAPI-04 that targets activated fibroblast cells, which are found in large numbers in many cancers and inflammatory conditions. Researchers want to see how well this scan detects cancer and other fibroblast-related diseases compared to existing imaging methods.
**You may be eligible if...**
- You are between 18 and 85 years old
- You have a cancer that can be confirmed by surgery or biopsy
- You are expected to survive at least 6 months and can attend follow-up visits
- You are a healthy volunteer with no chronic medical conditions (for the control group)
**You may NOT be eligible if...**
- You are pregnant or breastfeeding
- You are allergic to any component of the imaging drug
- You have severe liver or kidney problems
- You are participating in another clinical trial that could interfere
- You are too unwell to cooperate with the scan
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGInjection of 68Ga-NI-FAPI
Subjects were injected with 68Ga-NI-FAPI at 0.4-0.5mci/kg body weight
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07464132
Related Trials
Diabetes and Heart Disease Risk in Blacks
NCT000018531 location
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731152 locations
Hypertension Explored in Long-term Postpartum Follow-up in Later Life
NCT061870121 location
SMART to Optimize an Intervention to Maintain Health Improvements After Cardiac Rehabilitation
NCT068867891 location
Multicentre Hypertrophic Cardiomyopathy Registry
NCT073818941 location